[1] 王深明, 吴伟滨. 重视动脉粥样硬化相关发病机制的研究[J]. 中华血管外科杂志, 2017, 2:197-200. [2] 王斌驿, 李菲菲, 吴东方, 等. 巨噬细胞自噬在动脉粥样硬化中作用的研究进展[J]. 中国动脉硬化杂志, 2019, 27:439-444. [3] 赵正, 李琦, 尹婕, 等. 参莲提取物对ox-LDL诱导的巨噬细胞泡沫化和凋亡的药效学研究及提取部位活性比较[J]. 中国现代中药, 2019, 21:590-597. [4] Merckelbach S, van der Vorst EPC, Kallmayer M, et al. Expression and cellular localization of CXCR4 and CXCL12 in human carotid atherosclerotic plaques[J]. Thromb Haemost, 2018, 118:195-206. [5] 靳昭辉, 高普, 宋光熠, 等. 中药有效组分调控P38MAPK改善糖尿病动脉粥样硬化兔炎症反应的机理研究[J]. 云南中医学院学报, 2017, 40:1-5. [6] 马莹莹, 傅继华. 脂质、炎症在动脉粥样硬化发展机制中的研究进展[J]. 医学研究与教育, 2019, 36:1-7. [7] 郑鹏飞, 唐和蔚, 李红艳, 等. 巨噬细胞在动脉粥样硬化形成中的作用[J]. 现代生物医学进展, 2017, 17:784-786. [8] Gao JH, Yu XH, Tang CK. CXC chemokine ligand 12 (CXCL12) in atherosclerosis: an underlying therapeutic target[J]. Clin Chim Acta, 2019, 495:538-544. [9] Gao JH, He LH, Yu XH, et al. CXCL12 promotes atherosclerosis by downregulating ABCA1 expression via the CXCR4/GSK3β/β-cateninT120/TCF21 pathway[J]. J Lipid Res, 2019, 60:2020-2033. [10] Shafi S, Codrington R, Gidden LM, et al. Increased expression of phosphorylated forms of heat-shock protein-27 and p38MAPK in macrophage-rich regions of fibro-fatty atherosclerotic lesions in the rabbit[J]. Int J Exp Pathol, 2016, 97:56-65. [11] 刘洪, 唐旭, 汤志梅, 等. 绿茶多酚对兔主动脉粥样硬化斑块中磷酸化p38MAPK的影响[J]. 天然产物研究与开发, 2017, 29:1568-1572. [12] Ma J, Su H, Yu B, et al. CXCL12 gene silencing down-regulates metastatic potential via blockage of MAPK/PI3K/AP-1 signaling pathway in colon cancer[J]. Clin Transl Oncol, 2018, 20:1035-1045. |